Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203151
Status:
TERMINATED
Last Update Posted:
2011-04-12
First Post:
2005-09-13
Brief Title:
A Study to Evaluate the Tolerability Safety and Effectiveness of Edratide in the Treatment of Lupus
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multi-National Multi-Center Randomized Double-Blind Placebo-Controlled Multiple-Dose Parallel Group Study to Assess the Efficacy Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus SLE
Status:
TERMINATED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
TV-4710201 did not meet its primary endpoints in patients with SLE
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRELUDE
Brief Summary:
It is thought that Edratide may be able to reduce the symptoms of SLE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None